Biology Reference
In-Depth Information
EPOR. Recent data suggest that the receptor may actually be associated on the
cell surface without the natural ligand [13]. This finding suggests that it may
not merely be the dimerization event but an even more subtle conformational
change that occurs only after the natural ligand, rHuEPO, binds.
The quality and scope of the structural biology research in understanding
the interactions of EPOR with several different molecules has provided a
detailed analysis of the role of individual amino acids within the receptor.
These structures provide a rational for the design of the next generation of
rHuEPO biologics and may, in the future, provide the basis for a true small
molecule that could effectively allow the dimerization and conformational
change required for signal transduction comparable to the natural ligand.
References
1Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang
J et al. (1998) Efficiency of signalling through cytokine receptors depends critically on receptor
orientation.
Nature
395: 511-516
2 Cheetham JC, Smith DM, Aoki KH, Stevenson JL, Hoeffel TJ, Syed RS, Egrie J, Harvey TS
(1998) NMR structure of human erythropoietin and a comparison with its receptor bound confor-
mation.
Nat Struct Biol
5: 861-866
3 Bazan JF (1990) Structural design and molecular evolution of a cytokine receptor superfamily.
Proc Natl Acad Sci USA
87: 6934-6938
4 D'Andrea AD, Lodish HF, Wong GG (1989) Expression cloning of the murine erythropoietin
receptor.
Cell
57: 277-285
5 Philo JS, Aoki KH, Arakawa T, Narhi LO, Wen J (1996) Dimerization of the extracellular domain
of the erythropoietin (EPO) receptor by EPO: One high-affinity and one low-affinity interaction.
Biochemistry
35: 1681-1691
6 Damen JE, Krystal G (1996) Early events in erythropoietin-induced signaling.
Exp Hematol
24:
1455-1459
7Yoshimura A, Longmore G, Lodish HF (1990) Point mutation in the exo-plasmic domain of the
erythropoietin receptor resulting in hormone-independent activation and tumorigenicity.
Nature
348: 647-649
8 Elliott S, Lorenzini T, Yanagihara D, Chang D, Elliott G (1996) Activation of the erythropoietin
(EPO) receptor by bivalent anti-EPO receptor antibodies.
J Biol Chem
271: 24691-24697
9Wrighton NC, Farrell FX, Chang R, Kashyap AK, Barbone FP, Mulcahy LS, Johnson DL, Barrett
RW, Jolliffe LK, Dower WJ (1996) Small peptides as potent mimetics of the protein hormone ery-
thropoietin.
Science
273: 458-464
10 Livnah O, Stura EA, Johnson DL, Middleton SA, Mulcahy LS, Wrighton NC, Dower WJ, Jolliffe
LK, Wilson IA (1996) Functional mimicry of a protein hormone by a peptide agonist: The EPO
receptor complex at 2.8 A.
Science
273:464-471
11 Wrighton NC, Balasubramanian P, Barbone FP, Kashyap AK, Farrell FX, Jolliffe LK, Barrett RW,
Dower WJ (1997) Increased potency of an erythropoietin peptide mimetic through covalent dimer-
ization.
Nat Biotechnol
15: 1261-1265
12 Naranda T, Wong K, Kaufman RI, Goldstein A, Olsson L (1999) Activation of erythropoietin
receptor in the absence of hormone by a peptide that binds to a domain different from the hormone
binding site.
Proc Natl Acad Sci USA
96: 7569-7574
13 Constantinescu SN, Keren T, Socolovsky M, Nam H, Henis YI, Lodish HF (2001) Ligand-inde-
pendent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane
domain.
Proc Natl Acad Sci USA
98: 4379-4384
14 Narhi LO, Arakawa T, Aoki K, Wen J, Elliott S, Boone T, Cheetham J (2001) Asn to Lys muta-
tions at three sites which are N-glycosylated in the mammalian protein decrease the aggregation
of
Escherichia coli
-derived erythropoietin.
Protein Eng
14: 135-140
15 Bazan JF (1990) Haemopoietic receptors and helical cytokines.
Immunol To day
11: 350-354
